Your browser is no longer supported. Please, upgrade your browser.
Settings
SBIO [NYSE]
ALPS Medical Breakthroughs ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week3.64%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month12.35%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-2.84%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y-10.54%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year13.63%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range39.34 - 64.04 Perf YTD-6.60%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-25.28% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low21.63% ATR1.01
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)61.36 Volatility2.10% 2.21%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.60 Prev Close46.58
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume17.55K Price47.85
Recom- SMA204.06% SMA505.20% SMA200-4.38% Volume10,477 Change2.73%
Aug-20-20 04:58PM  
Jun-23-20 11:10AM  
Apr-14-20 04:00PM  
Feb-21-20 11:42AM  
Feb-10-20 01:40PM  
Dec-26-19 02:30PM  
Dec-24-19 12:15PM  
Dec-23-19 12:00PM  
Dec-20-19 02:00PM  
Dec-12-19 08:00AM  
Dec-10-19 04:16PM  
10:10AM  
Dec-02-19 02:40PM  
Nov-27-19 11:05AM  
10:15AM  
Nov-21-19 12:15PM  
Nov-01-19 11:10AM  
Oct-31-19 12:25PM  
Oct-30-19 10:43AM  
Oct-23-19 04:24PM  
10:10AM  
Sep-09-19 04:55PM  
Sep-03-19 05:46PM  
Aug-05-19 12:00PM  
Jun-24-19 04:23PM  
Jun-18-19 09:55AM  
Jun-17-19 03:22PM  
May-15-19 01:00PM  
May-06-19 06:05PM  
Apr-11-19 03:33PM  
Apr-10-19 03:21PM  
02:27PM  
Mar-06-19 05:05PM  
Feb-28-19 01:00PM  
Feb-27-19 03:00PM  
Feb-26-19 11:15AM  
Feb-25-19 01:59PM  
Feb-14-19 01:53PM  
Jan-23-19 09:16AM  
Jan-22-19 10:15AM  
Jan-14-19 01:00PM  
Jan-07-19 01:56PM  
Dec-27-18 02:30PM  
Nov-20-18 02:03PM  
Oct-23-18 09:18AM  
Oct-10-18 03:30PM  
Sep-28-18 07:37AM  
Sep-06-18 11:00AM  
Jul-12-18 03:23PM  
Jul-03-18 04:42PM  
Jul-02-18 03:23PM  
Jun-28-18 12:25PM  
May-31-18 04:36PM  
May-21-18 02:20PM  
10:40AM  
May-11-18 04:18PM  
Apr-16-18 08:00AM  
Mar-27-18 12:42PM  
Jan-11-18 10:57AM  
Jan-10-18 12:18PM  
Dec-28-17 02:27PM  
Dec-22-17 04:16PM  
Sep-12-17 03:08PM  
Aug-29-17 12:44PM  
Aug-28-17 02:37PM  
Jul-06-17 06:07PM  
Jun-19-17 05:18PM  
Jun-01-17 01:12PM  
May-18-17 10:19AM  
May-08-17 05:42PM  
Mar-21-17 12:19PM  
Mar-01-17 04:14PM  
08:59AM  
Feb-23-17 11:45AM  
Jan-12-17 12:00PM  
10:08AM  
Dec-08-16 03:00PM  
Nov-14-16 01:54PM  
Nov-10-16 09:55AM  
Nov-01-16 12:46PM  
11:12AM  
Oct-27-16 12:19PM  
Oct-21-16 09:54AM  
Sep-21-16 11:23AM  
Sep-14-16 02:19PM  
Sep-12-16 02:47PM  
Aug-19-16 12:14PM  
Aug-01-16 08:00AM  
Jul-20-16 02:23PM  
Jul-05-16 10:53AM  
Jun-22-16 10:40AM  
Apr-15-16 11:33AM  
Apr-07-16 11:30AM  
Apr-06-16 11:38AM  
Feb-05-16 09:48AM  
Feb-03-16 01:05PM  
10:17AM  
Feb-02-16 09:30AM  
Dec-31-15 09:30AM  
Dec-30-15 10:45AM  
The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.